KLAS Report Shows Hologic Continuing to Lead the U.S. Breast Tomosynthesis Market with Genius™ 3D MAMMOGRAPHY™ Exams
Mammography customers highlight Hologic's high image quality, strong customer support, and market-leading product innovations

MARLBOROUGH, Mass., June 15, 2016 /PRNewswire/ -- Hologic (NASDAQ: HOLX) announced today that the Company received top marks from U.S. mammography providers in a new independent report from KLAS Research, with 96 percent of customers reporting that Hologic systems are worth the investment.1

In the KLAS report, Tomosynthesis 2016, doctors, directors of radiology and c-suite executives scored Hologic highest in overall product satisfaction and confidence that the company will continue to lead the development of the tomosynthesis market. The in-depth survey, which was not commissioned by Hologic, surveyed decision makers at 48 organizations with breast tomosynthesis systems installed.

"Hologic seems to be the only company that really understands the tomosynthesis market," a director of radiology told KLAS. "It was clear from our implementation and our usage of their system that they are a full generation ahead of other vendors. Everybody else is playing catch up." Hologic has scored highest in the mammography market in all five KLAS Tomosynthesis reports.

Provider respondents noted Hologic's high image quality, strong customer service, and implementation guidance as key reasons for new system purchases. Additionally, more than 91 percent of respondents reported a sense of confidence that Hologic's pace of development will continue to allow for leadership in tomosynthesis product innovation — a significantly higher score than that of other manufacturers.

"In the new KLAS Tomosynthesis report, providers conclude once again that the most-preferred mammogram technology available is Hologic's Genius™ 3D MAMMOGRAPHY™ exam," said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions. "Hologic is committed to leading this market, and we believe there is no company more dedicated to this industry. The KLAS report shows that mammography providers are seeing and feeling our strong investment in research and development, as well as our commitment to customers. We are committed to developing for our customers the best products that deliver superior clinical value, patient satisfaction and cost effectiveness."

The Genius™ 3D MAMMOGRAPHY™ exam is FDA-approved and only available on the Hologic Selenia® Dimensions® system. The Genius™ exam is the only mammogram proven to reduce unnecessary callbacks by up to 40 percent, and detect 41 percent more invasive cancers than conventional mammography alone.2,3 Additional information, as well as a locator to find imaging sites offering Genius™ 3D MAMMOGRAPHY™ exams, can be found at http://mygenius3d.com/.

About KLAS Research

KLAS is a research and insights firm on a global mission to improve healthcare delivery by amplifying the provider's voice. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software, services, and medical equipment to deliver timely reports, trends and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving vendor performance. Follow KLAS on Twitter at www.twitter.com/KLASresearch.

About Hologic

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.

Hologic, The Science of Sure, 3D Mammography, Dimensions, Genius, and Selenia are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based

Media Contact:
Jane Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com

Investor Contact
Michael Watts
858.410.8588
michael.watts@hologic.com

1 "Tomosynthesis 2016. Performance Report." © 2016 KLAS Enterprises, LLC. All rights reserved. www.KLASresearch.com
2 Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014;311(24):2499-2507.
3 Rose SL, Tidwell AL, Bujnoch LJ, et al. Implementation of breast tomosynthesis in a routine screening practice: an observational study. AJR Am J Roentgenol. 2013;200(6):1401-1408.

SOURCE Hologic, Inc.